| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-28 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.890 | -0.190 | 1.7000 | ||||
| REV | 173.420M | 189.406M | 15.986M |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Sarepta Therapeutics (NASDAQ: SRPT) through any online brokerage.
Other companies in Sarepta Therapeutics’s space includes: Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Sarepta Therapeutics (NASDAQ: SRPT) was reported by Morgan Stanley on January 18, 2022. The analyst firm set a price target for 92.00 expecting SRPT to rise to within 12 months (a possible 32.01% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $69.69 last updated Fri Jan 28 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Sarepta Therapeutics.
Sarepta Therapeutics’s $Q4 earnings are confirmed for after-market on February 28, 2022.
There is no upcoming split for Sarepta Therapeutics.
Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.